Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1412)
Drug Name
Revefenacin
Synonyms
Revefenacin; Revefenacin (USAN/INN); Revefenacin [INN]; Revefenacin [USAN:INN]; Revefenacin [WHO-DD]; SB17262; SCHEMBL356480; TD-4208; TD4208; Yupelri; 864750-70-9; BCP15793; CHEMBL3833319; DB11855; EX-A1722; G2AE2VE07O; GSK-1160724; GSK-1160724;[1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate; GSK1160724; GTPL10129; UNII-G2AE2VE07O; [1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate
Indication Chronic obstructive pulmonary disease [ICD11: CA22] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 597.7 Topological Polar Surface Area 108
Heavy Atom Count 44 Rotatable Bond Count 11
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 6
Cross-matching ID
PubChem CID
11753673
CAS Number
864750-70-9
TTD Drug ID
D0K1ST
Formula
C35H43N5O4
Canonical SMILES
CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
InChI
1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)
InChIKey
FYDWDCIFZSGNBU-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
THRX-177860 DM016728
146019671
Multi-steps Reaction - N-dealkylation; oxidation 1 [3]
THRX-195518 DM016187
57459433
Hydrolysis - Hydrolysis 1 [3]
THRX-609075 DM016726
146019391
Hydrolysis - Hydrolysis 1 [3]
THRX-697795 DM016687
138059654
Multi-steps Reaction - N-dealkylation; reduction 1 [3]
Unclear DM009999 N. A. Unclear - Unclear 1 [2]
THRX-193305 DM017904 N. A. Oxidation - N-dealkylation 2 [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR009525 Revefenacin THRX-195518 Hydrolysis - Hydrolysis Unclear [3]
MR009527 Revefenacin THRX-609075 Hydrolysis - Hydrolysis Unclear [3]
MR009528 Revefenacin THRX-177860 Multi-steps Reaction - N-dealkylation; oxidation Unclear [3]
MR009529 Revefenacin THRX-697795 Multi-steps Reaction - N-dealkylation; reduction Unclear [3]
MR009530 Revefenacin Unclear Unclear - Unclear CYP2D6 [2]
MR009526 THRX-195518 THRX-193305 Oxidation - N-dealkylation Unclear [3]
⏷ Show the Full List of 6 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[2]
References
1 Revefenacin was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017 Nov 2;18(1):182.
3 Revefenacin Absorption, Metabolism, and Excretion in Healthy Subjects and Pharmacological Activity of Its Major Metabolite

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.